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In patients presenting with acute coronary syndrome (ACS) the optimal duration of dual-antiplatelet 
therapy after drug-eluting stent (DES) implantation remains unclear. At 6 months after intervention, 
patients receiving clopidogrel were randomly assigned to either a further 6-month period of placebo 
or clopidogrel. The primary composite endpoint was death, myocardial infarction, stent thrombosis, 
stroke, or major bleeding 9 months after randomization. The ISAR-SAFE trial was terminated early 
due to low event rates and slow recruitment. 1601/4000 (40.0%) patients presented with ACS and were 
randomized to 6 (n = 794) or 12 months (n = 807) clopidogrel. The primary endpoint occurred in 14 
patients (1.8%) receiving 6 months of clopidogrel and 17 patients (2.2%) receiving 12 months; hazard 
ratio (HR) 0.83, 95% confidence interval (CI) 0.41–1.68, P = 0.60. There were 2 (0.3%) cases of stent 
thrombosis in each group; HR 1.00, 95% CI 0.14–7.09, P = >0.99. Major bleeding occurred in 3 patients 
(0.4%) receiving 6 months clopidogrel and 5 (0.6%) receiving 12 months; HR 0.60, 95% CI 0.15–2.49, 
P = 0.49. There was no significant difference in net clinical outcomes after DES implantation in ACS 
patients treated with 6 versus 12 months clopidogrel. Ischaemic and bleeding events were low beyond 
6-months.
Patients presenting with acute coronary syndrome (ACS) are at higher risk of subsequent ischaemic events com-
pared to those with stable angina. Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and an adenosine 
diphosphate receptor antagonist reduces ischaemic events in this population – although increases bleeding – 
regardless of whether an invasive or medical treatment strategy is chosen1,2. Improvements in stent design, deliv-
ery technique, and the widespread adoption of DAPT have reduced the rate of stent thrombosis after PCI3.
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Although prolonged DAPT reduces ischaemic endpoints after intervention the increased risk of bleeding 
may limit the clinical efficacy and the optimal duration of DAPT after percutaneous coronary intervention (PCI) 
in patients presenting with ACS remains controversial. U.S. and European guidelines currently recommend 12 
months of DAPT for ACS patients, without an indication for oral anticoagulation, undergoing PCI; this recom-
mendation is based on previous observational and registry data raising concern about the ongoing risk of stent 
thrombosis with early generation DES4,5 and evidence of incremental benefit over 12 months demonstrated in 
the CURE trial1. With respect to the treatment effect of shorter duration (<12 months) DAPT after PCI, ran-
domised trials have been limited by methodological difficulties, including inadequate sample size6–11, however, 
meta-analyses of available data have shown lower rates of bleeding with no increase in ischaemic events in those 
treated with shorter duration DAPT12,13.
The ISAR-SAFE study was designed to assess 6 versus 12 months clopidogrel for patients undergoing DES 
implantation for both stable coronary disease and ACS11. The trial demonstrated non-inferiority of the 6-month 
clopidogrel regimen in terms of net clinical outcome – the composite of death, myocardial infarction, stent 
thrombosis, stroke and major bleeding at 9 months after randomization (15 months after DES implantation). The 
study findings were limited by lower than expected event rates and early termination due to slow enrolment. This 
ISAR-SAFE ACS report is a prespecified subgroup analysis that aims to examine the treatment effect of 6 versus 
12 months clopidogrel for ACS patients enrolled in the ISAR-SAFE trial.
Methods
The current report is a prespecified subgroup analysis of the ACS patients recruited for the ISAR-SAFE 
trial. Full details of the ISAR-SAFE trial design have previously been published11,14. ISAR-SAFE was an 
investigator-initiated, international, multicenter, randomised, double-blind, placebo-controlled, non-inferiority 
trial that sought to assess 6 months versus 12 months duration of clopidogrel treatment for patients undergoing 
DES implantation. Patients were eligible for enrolment if they were receiving clopidogrel therapy at 6 (−1/+2) 
months after DES implantation and had provided written informed consent. Major exclusion criteria were age 
≤ 18 years, clinical symptoms or proof of ischemia and/or angiographic lesions requiring revascularization, pre-
vious stent thrombosis, DES implantation in the left main coronary artery, myocardial infarction during the 6 
months after DES implantation, malignancies or other comorbid conditions with a life expectancy of <1 year or 
that may result in protocol noncompliance, planned major surgery within 6 months with the need to discontinue 
antiplatelet therapy, active bleeding, bleeding diathesis, history of intracranial bleeding, oral anticoagulation, 
and known allergy or intolerance of the study medication. Enrolled patients were subsequently randomised 1:1 
to receive either placebo or clopidogrel for 6 months, in addition to acetyl salicylic acid, and other medications 
prescribed at the discretion of the treating physician. All patients were scheduled to undergo clinical follow-up 
at 30 days, 6 months and 9 months after randomization. The primary endpoint was the composite of death, 
myocardial infarction, stent thrombosis (definite or probable), stroke, or Thrombolysis in Myocardial Infarction 
(TIMI) major bleeding at 9 months after randomization, i.e. 15 months after the index intervention. Secondary 
endpoints were the individual components of the primary endpoint. The study was conducted in accordance with 
the Declaration of Helsinki. The Ethics Committee of the Technische Universität München (Ismaninger Straße 
22, 81675 München, Germany), and each participating center, approved the study. All patients provided written 
informed consent.
Statistical Considerations. The statistical design of the non-inferiority ISAR-SAFE study has been 
described in detail previously11,14. Categorical variables were summarized using frequencies and proportions and 
compared using the chi-square test or Fisher’s exact test, as appropriate. Continuous data were summarized using 
mean ± standard deviation or median [interquartile range] and compared using Student’s t-test or nonparametric 
Wilcoxon rank-sum test, respectively. Cumulative event rates were calculated by the Kaplan Meier method and a 
Cox proportional hazards model was used for the comparison of the 2 study groups. The primary end point was 
also assessed in subgroups defined by age, gender, presence of diabetes mellitus, previous myocardial infarction, 
complexity of the treated lesion (complex lesions defined as B2 and C per the modified American College of 
Cardiology/American Heart Association Task Force classification), impaired left ventricular function (<55%), 
early generation DES, and premature study drug discontinuation. Software R (version 2.15.2, The R Foundation 
for Statistical Computing) was used for statistical analyses. The significance level was set at a two-sided alpha level 
of 0.05.
Results
Patients and Procedures. Between September 2006 and April 2014 a total of 1601/4000 (40.0%) patients 
enrolled in the ISAR-SAFE trial presented with ACS: 794 were randomly assigned to receive 6 months of clopi-
dogrel and 807 to 12 months.
Table 1 summarizes the baseline clinical and demographic characteristics according to treatment allocation to 
6 or 12 months of clopidogrel. Angiographic and procedural characteristics at the time of index intervention are 
shown in Table 2. Overall 734/1601 (45.8%) patients presented with myocardial infarction at the index interven-
tion: 410 patients (25.6%) with an acute non-ST elevation myocardial infarction and 324 (20.2%) with ST eleva-
tion myocardial infarction. Table 3 shows the medication patients were receiving at the time of randomization.
Premature discontinuation of the study drug was recorded in 12.0% of the patients assigned to 6 months of 
clopidogrel and 14.7% of the patients assigned to 12 months of clopidogrel (p = 0.10).
Clinical Outcomes. There was no signal for interaction to suggest an overall treatment effect in this ACS 
population (Pinteraction = 0.72). Clinical follow-up at 9 months was available for all but 84 patients, 34 assigned to 6 
months of clopidogrel (4.3%) and 50 patients (6.3%) assigned to 12 months; P = 0.08. In patients with incomplete 
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9-month follow-up, the median duration of follow-up was 190 [IQR 180–226] days. A total of 21 patients (1.4%), 
8 patients assigned to 6 months of clopidogrel and 13 patients assigned to 12 months of clopidogrel, had a 
follow-up shorter than 6 months (P = 0.28).
Clinical outcomes according to study group are reported in Table 4. At 9 months, the composite primary 
endpoint of death, myocardial infarction (MI), stent thrombosis, stroke or major bleeding was observed in 14 
patients (1.8%) assigned to 6 months of clopidogrel and 17 patients (2.2%) assigned to 12 months; hazard ratio 
(HR) 0.83, 95% confidence interval (CI) 0.41–1.68, P = 0.60 (graphical representation of primary endpoint shown 
in Fig. 1).
Regarding the secondary endpoints, 5 patients (0.6%) assigned to 6 months of clopidogrel and 7 patients 
(0.9%) assigned to 12 months of clopidogrel died within 9 months; HR 0.72, 95% CI 0.23–2.26, P = 0.57. There 
were 4 cases of definite stent thrombosis, 2 (0.3%) in patients assigned to 6 months of clopidogrel and 2 (0.3%) in 
patients assigned to 12 months of clopidogrel; HR 1.00, 95% CI 0.14–7.09, P = >0.99. The rates of MI and stroke 
were low and comparable in both study groups (MI: 6 patients [0.8%] vs. 8 patients (1.0%); HR 0.75, 95% CI 
0.26–2.17, P = 0.60 and stroke: 3 patients [0.4%] vs. 2 [0.3%]; HR 0.75, 95% CI 0.26–2.17, P = 0.65, in the 6 month 
and 12 month groups respectively). The composite of death, MI, stent thrombosis, or stroke is shown in Fig. 2.
TIMI major bleeding was observed in 1 patient (0.1%) assigned to 6 months of clopidogrel and in 2 patients 
(0.3%) assigned to 12 months of clopidogrel; HR 0.50, 95% CI 0.05–5.55, P = 0.58 (Fig. 3). There was no sig-
nificant reduction in the rate of TIMI minor bleeding in patients receiving 6 months of clopidogrel (2 events 
[0.3%] vs. 3 events [0.4%]; HR 0.67, 95% CI 0.11–3.96, P = 0.66), nor the composite of TIMI major and minor 
bleeding (3 events [0.4%] versus 5 events; HR 0.60, 95% CI 0.14–2.52, P = 0.49) (Fig. 4). Bleeding, according to 
the Bleeding Academic Research Consortium (BARC), ≥ class 2 was observed in 9 patients (1.1%) assigned to 6 
months clopidogrel and 17 patients (2.1%) assigned to 12 months clopidogrel (p = 0.12).
Results of subgroup analysis are shown in Fig. 5. There was no significant interaction regarding the primary 
endpoint between treatment effect and age (Pinteraction = 0.06), diabetic versus non-diabetic patients (Pinteraction = 0.66), 
previous MI versus no previous MI (Pinteraction = 0.22), normal versus impaired LV function <55% (Pinteraction = 0.53), 
simple versus complex lesion morphology (ACC/AHA classification B2 or C) (Pinteraction = 0.26), early versus new 
generation DES (Pinteraction = 0.95), and premature discontinuation of study drug (Pinteraction = 0.11).
Discussion
This prespecified subgroup analysis of the ISAR-SAFE study assessed the treatment effect of 6 months versus 12 
months clopidogrel for patients presenting with ACS and receiving treatment with a DES. The main finding is 
that event rates of the primary composite end point were low and were not statistically significant between the 
two groups. This study was investigator-initiated, industry-independent, and to date is the only double-blind, 
placebo-controlled trial that randomised ACS patients to shorter versus standard duration DAPT after DES 
implantation.
Current guideline recommendations regarding the duration of DAPT after DES implantation were drawn 
from first-generation DES observational data that indicated a small ongoing risk of ischaemic events and stent 
thrombosis beyond 12 months4,15. Subsequent evolutions in DES drug and polymer coatings reduced the risk of 
late stent thrombosis in 2nd generation devices16, ultimately raising the question of whether early cessation of 
DAPT following 2nd generation DES implantation could improve overall clinical outcomes by reducing bleeding 
complications. Observational data identified ACS at presentation as an independent risk factor for stent throm-
bosis4 in comparison to those with stable coronary disease, and this is reflected in the guidelines by a longer 
recommended period of DAPT for ACS patients undergoing stent implantation17,18. However, ACS patients have 
frequently been underrepresented in subsequent trials exploring duration of DAPT after stent implantation, often 
as a result of inherent methodological difficulties, and the appropriate treatment strategy remains unclear.
Prior to our study, a number of randomised trials explored <12 months versus ≥12 months duration of DAPT 
after stent implantation. Several of these trials excluded, or restricted the inclusion, of high-risk patients6,8–10,19. 
Six Months Clopidogrel (n = 794) Twelve Months Clopidogrel (n = 807) P
Age, years 64.8 [57.4–72.8] 64.7 [56.4–73.0] 0.77
Female 156/794 (19.6) 144/807 (17.8) 0.36
Arterial hypertension 685/791 (86.6) 719/807 (89.1) 0.13
Hypercholesterolemia 646/793 (81.5) 666/807 (85.5) 0.58
Diabetes mellitus 169/793 (21.3) 198/807 (24.5) 0.13
 Insulin-requiring 53/793 (6.7) 70/807 (8.7) 0.14
Family history 253/755 (33.5) 246/763 (32.2) 0.60
Smoking status
 Active smoker 141/793 (17.8) 136/807 (16.9) 0.62
 Former smoker 273/793 (34.4) 291/807 (36.1) 0.49
History of prior myocardial infarction 181/792 (22.9) 178/807 (22.1) 0.70
History of prior coronary artery bypass graft 47/787 (6.0) 59/798 (7.4) 0.26
Body mass index, kg/m2 27.6 [24.7–29.6] 27.7 [24.7–30.3] 0.74
Table 1. Baseline Clinical and Demographic Characteristics at the Time of Randomization. Data are shown 
as number (percentage) or median [interquartile range].
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Six Months Clopidogrel (n = 794) Twelve Months Clopidogrel (n = 807) P
Clinical presentation 0.89
 Unstable angina 429/794 (54.0) 438/807 (54.3)
 NSTEMI 207/794 (26.1) 203/807 (25.2)
 STEMI 158/794 (19.9) 166/807 (20.6)
Reduced left ventricular- ejection fraction (<55%) 205/726 (28.2) 220/744 (29.6) 0.57
Number of diseased vessels 0.41
 1 364/794 (45.8) 345/807 (42.8)
 2 237/794 (29.8) 262/807 (32.5)
 3 193/794 (24.3) 200/807 (24.8)
Multivessel disease 430/794 (54.2) 462/807 (57.2) 0.21
Target vessel 0.57
 LAD 329/794 (41.1) 323/807 (40.0)
 LCx 205/794 (25.8) 194/807 (24.0)
 RCA 245/794 (30.9) 279/807 (34.6)
 LMCA 3/794 (0.4) 2/807 (0.2)
 Bypass graft 12/794 (1.5) 9/807 (1.1)
Lesion characteristics
 Complex lesion 305/788 (38.7) 335/797 (42.0) 0.18
 Chronic total occlusion 62/794 (7.8) 48/804 (6.0) 0.15
 Bifurcation lesion 134/794 (16.9) 139/804 (17.3) 0.83
Vessel size, mm 3.0 [2.75–3.5] 3.0 [2.75–3.5] 0.48
Multilesion intervention 284/794 (35.8) 298/807 (36.9) 0.63
Drug-eluting stent type 0.18
 PES 21/794 (2.6) 17/807 (2.1)
 Early generation SES 95/794 (12.0) 89/807 (11.0)
 New generation SES 126/794 (15.9) 134/807 (16.6)
 EES 368/794 (46.3) 402/807 (49.8)
 ZES 123/794 (15.5) 95/807 (11.8)
 BES 56/794 (7.1) 63/807 (7.8)
 BVS 1/794 (0.1) 0/807 (0.0)
 BMS 4/794 (0.5) 3/807 (0.4)
 Drug-coated balloon 0/794 (0.4) 4/807 (0.5)
 POBA 0/794 (0.0) 0/807 (0.0)
Number of stents 1.64 ± 0.94 1.68 ± 0.93 0.36
Total stented length, mm 28 [18–44] 28 [18–45.75] 0.36
Table 2. Angiographic and Procedural Characteristics at the Time of Index Intervention. Data are shown 
as number (percentage), mean ± standard deviation or median [interquartile range]. NSTEMI  =  Non-ST 
segment elevation myocardial infarction, STEMI  =  ST elevation myocardial infarction, LAD  =  left anterior 
descending, LCx  =  left circumflex, RCA  =  right coronary artery, LMCA  =  left main coronary artery, PES  =  
paclitaxel-eluting stent, SES  =  sirolimus-eluting stent, EES  =  everolimus-eluting stent, ZES  =  zotarolimus-
eluting stent, BES  =  biolimus-eluting stent, BVS  =  bioresorbable everolimus-eluting vascular scaffold, 
POBA  =  plain balloon angioplasty.
Six Months Clopidogrel (n = 794) Twelve Months Clopidogrel (n = 807) P
Acetylsalicylic acid 794/794 (100) 806/807 (99.9)† 0.32
Beta blocker 681/794 (85.8) 703/807 (87.1) 0.43
ACE inhibitor* 509/794 (64.1) 545/807 (67.5) 0.15
Angiotensin II receptor blocker 146/793 (18.4) 148/806 (18.4) 0.98
Calcium antagonist 148/793 (18.7) 152/807 (18.8) 0.93
Diuretic 233/792 (29.4) 227/807 (28.1) 0.57
Proton pump inhibitor 215/787 (27.3) 224/802 (27.9) 0.79
Statin 763/794 (96.1) 765/807 (94.8) 0.21
Table 3. Medication at Randomisation. Data are shown as number (percentage). *ACE = Angiotensin-
Converting Enzyme. †One patient in the twelve months clopidogrel group was treated with cilostazol instead of 
acetylsalicylic acid.
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Of the studies to include high-risk patients, this population has been underrepresented in some cases20, and the 
results from the largest available randomised trial are limited by underpowering for the primary endpoint, and 
an open-label design7.
Prolongation of DAPT therapy beyond the guideline recommended 12-month period may be an alternative 
strategy for ACS patients at low bleeding risk. For example, the ‘DAPT’ trial found lower ischaemic events with 30 
months, compared to 12 months, of clopidogrel after DES at a cost of increased bleeding21. Recent meta-analyses 
including randomised trials of longer versus standard duration DAPT also support the notion that ischaemic 
endpoints and cardiovascular, but not overall, mortality are improved by ongoing therapy: counter-balanced by 
increased non-fatal major bleeding22,23.
In our double-blind, placebo-controlled study we included ACS patients, who remained stable six months 
after index PCI. The primary endpoint was a composite of ischaemic and bleeding events, which seeks to reflect 
net clinical benefit to the patient. Although conclusions from subgroup analyses must be carefully drawn, the 
main finding of low event rates and similar net clinical outcomes in ACS patients receiving clopidogrel for 6 
Six Months 
Clopidogrel (n = 794)
Twelve Months 
Clopidogrel (n = 807) HR (95% CI) P
Primary endpoint — composite of death, myocardial infarction, 
definite or probable stent thrombosis, stroke or TIMI* major 
bleeding)
14 (1.8) 17 (2.2) 0.83 (0.41–1.68) 0.60
Secondary endpoints
 Death 5 (0.6) 7 (0.9) 0.72 (0.23–2.26) 0.57
 Myocardial infarction 6 (0.8) 8 (1.0) 0.75 (0.26–2.18) 0.60
 Definite or probable stent thrombosis 2 (0.3) 2 (0.3) 1.00 (0.14–7.09) >0.99
 Stroke 3 (0.4) 2 (0.3) 1.51 (0.25–9.01) 0.65
 TIMI* major Bleeding 1 (0.1) 2 (0.3) 0.50 (0.05–5.55) 0.58
Composite of death, myocardial infarction, definite or probable 
stent thrombosis, or stroke) 13 (1.7) 16 (2.0) 0.82 (0.39–1.69) 0.59
Definite stent thrombosis 2 (0.3) 2 (0.3) 1.00 (0.14–7.09) >0.99
TIMI* minor bleeding 2 (0.3) 3 (0.4) 0.67 (0.11–4.01) 0.66
TIMI* major or minor bleeding 3 (0.4) 5 (0.6) 0.60 (0.14–2.52) 0.49
Table 4. Clinical Outcomes at 9 Months. Data are shown as number (percentage). *TIMI  =  Thrombolysis in 
Myocardial Infarction.
Figure 1. Primary Composite Endpoint of Death, Myocardial Infarction, Stent Thrombosis, Stroke or 
TIMI Major Bleeding at 9 Months in the Two Study Groups of Six and Twelve Months Clopidogrel Therapy. 
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months, compared with 12 months, lends some support to the hypothesis that a shorter duration of DAPT may 
also be a suitable management strategy for selected patients. Although this study is not powered to interpret fur-
ther subanalysis, no heterogeneity of treatment effect was seen amongst other ACS population subgroups.
The ISAR-SAFE ACS substudy has a number of limitations that should be recognized. Firstly, patients in 
the ISAR-SAFE study were randomised 6 months after index PCI; as a result, there was an unavoidable bias 
toward enrolment of patients at lower ischaemic and bleeding risk and the findings cannot be generalized to 
Figure 2. Composite of Death, Myocardial Infarction, Stent Thrombosis or Stroke at 9 Months in the Two 
Study Groups of Six and Twelve Months Clopidogrel Therapy. 
Figure 3. TIMI Major Bleeding at 9 Months in the Two Study Groups of Six and Twelve Months 
Clopidogrel Therapy. 
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the ACS population as a whole. Additionally, the requirement for patients to present to hospital 6 months after 
stent implantation, for eligibility assessment, is likely to introduce an element of bias in favour of enrolment of 
lower-risk ACS patients. Secondly, referring physicians may have preferred not to refer higher-risk ACS patients 
for consideration of enrolment given the potential for randomisation to shorter-term DAPT and a perceived 
increased risk of adverse events. Thirdly, although statistical power calculations were derived from historical 
Figure 4. Composite of TIMI Major or Minor Bleeding at 9 Months in the Two Study Groups of Six and 
Twelve Months Clopidogrel Therapy. 
Figure 5. Incidence of The Primary Endpoint in Subgroup Analysis – DES = Drug Eluting Stent. 
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trials using first-generation DES, 89% of patients enrolled in ISAR-SAFE received second-generation stents; these 
stents are associated with a lower rate of stent thrombosis and other complications compared with first-generation 
DES, leading to a reduction in ischaemic endpoints. Finally, novel P2Y12 inhibitors have emerged since the 
beginning of enrolment for the ISAR-SAFE study. ACS patients treated with ticagrelor have lower rates of ischae-
mic events compared to those receiving clopidogrel24 and patients with a previous history of myocardial infarc-
tion benefit from prolonged treatment with ticagrelor25. Given their proven superiority to clopidogrel, current 
guidelines recommend novel P2Y12 inhibitors as the preferred second antiplatelet agent for patients presenting 
with ACS17,18 and patients treated with these agents would not have been eligible for inclusion in ISAR-SAFE. 
Therefore, although this study includes the largest cohort of ACS patients randomised to shorter versus standard 
duration DAPT after DES implantation, and event rates are comparable to similarly designed trials10, we acknowl-
edge the underpowering of the trial in relation to detection of differences in clinical outcomes. However, the data 
presented here remain relevant for inclusion in future meta-analyses exploring shorter versus standard duration 
of DAPT after DES.
In summary, whilst this study was underpowered for the primary endpoint, the ISAR-SAFE ACS subgroup 
analysis demonstrated low event rates and no statistically significant difference in net clinical outcomes, defined 
as death, myocardial infarction, stroke, or TIMI major bleeding, for patients presenting with ACS receiving 6 
months versus 12 months clopidogrel after DES implantation.
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